Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus ORAMORPH SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus ORAMORPH SR.
NUCYNTA ER vs ORAMORPH SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
None Documented
None Documented
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic